Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Abroad (travel likely)RecruitingPHASE2

Conditions

Peripheral Blood Stem Cell Transplantation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chinese PLA General Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Daihong Liu, doctor) · daihongrm@163.com · 86-13681171597
Contact: Study coordinator (Liping Dou, doctor) · lipingruirui@163.com · 86-13681207138
Contact: Principal Investigator (Daihong Liu, doctor)

Study leads

Daihong Liu
Principal Investigator
Chinese PLA General Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Peripheral Blood Stem Cell Transplantation · Hematopoietic Stem Cell Transplantation

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Bethesda, United States

Shingrix In Recipients of Allogeneic Transplants

Bone Marrow Transplant · Stem Cell Transplant

Abroad (travel likely)RecruitingPHASE2

Aurora, United States

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

Stem Cell Transplant · Allogeneic

Abroad (travel likely)Recruiting

Houston, United States · Houston, United States

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Leukemia · Myelodysplasia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Columbus, United States